BioNTech

BioNTech的79.85欧元困局：管理真空与临床密集期叠加，市场在等什么？

angelina -

BioNTech Targets First Oncology Approval in 2026 While Spinning Off mRNA Legacy

angelina -

BioNTech转型暗礁：分拆倒计时与临床试验诉讼双重夹击

kashif hafeez -

BioNTech Builds in Australia Even as It Cuts Jobs and Sheds Factories

BioNTech的六月大考：分拆截止日逼近，Moderna接盘工厂添变数

kashif hafeez -

BioNTech双重博弈：技术面深陷泥潭，6+7项临床数据待破局

kashif hafeez -

BioNTech转型十字路口：百亿现金押注肿瘤赛道，市场为何仍在观望？

BioNTech里程碑时刻：首个肿瘤药FDA申请在即，15项三期临床蓄势待发

angelina -

BioNTech’s First US Cancer Filing Arrives With a Leadership Vacuum and a Pipeline That Investors Can’t Ignore

kashif hafeez -

BioNTech启动10亿美元回购与1800人裁员：下半年7项关键临床数据待揭晓

BioNTech的估值岔路口：巨额现金回购与临床数据能否弥合分析师分歧？

angelina -

BioNTech’s Pipeline Grows Faster Than Its Stock, Leaving a 36% Analyst Upside on the Table

kashif hafeez -

BioNTech转型阵痛：172亿欧元现金在手，市场为何仍给“折扣价”？

BioNTech’s Radical Pivot: Inside the Founder Exit, 1,860 Job Cuts and a $17 Billion Cancer Wager

Brett Shapiro -

BioNTech核心研发团队出走：一场从新冠王者到肿瘤新贵的“断腕式”转型

kashif hafeez -
1...567...15Page 6 of 15